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Abstract 
Glioblastoma, the most common and malignant primary brain tumor, always recurs after standard 
treatment. Therefore, promising new therapeutic approaches are needed. Short-range 
Auger-electron-emitters carry the ability of causing highly damaging radiation effects in cells. The aim of 
this study was to test the effect of [125I]5-Iodo-2’-deoxyuridine (125I-UdR, a radioactive 
Auger-electron-emitting thymidine analogue) Auger-therapy on immature glioblastoma spheroid 
cultures and orthotopic xenografted glioblastoma-bearing rats, the latter by means of 
convection-enhanced delivery (CED). Moreover, we aimed to determine if the therapeutic effect could 
be enhanced when combining 125I-UdR therapy with the currently used first-line chemotherapeutic 
agent temozolomide. 125I-UdR significantly decreased glioblastoma cell viability and migration in vitro and 
the cell viability was further decreased by co-treatment with methotrexate and/or temozolomide. 
Intratumoral CED of methotrexate and 125I-UdR with and without concomitant systemic temozolomide 
chemotherapy significantly reduced the tumor burden in orthotopically xenografted 
glioblastoma-bearing nude rats. Thus, 100% (8/8) of the animals survived the entire observation period 
of 180 days when subjected to the combined Auger-chemotherapy while 57% (4/7) survived after the 
Auger-therapy alone. No animals (0/8) treated with temozolomide alone survived longer than 50 days. 
Blood samples and post-mortem histology showed no signs of dose-limiting adverse effects. In 
conclusion, the multidrug approach consisting of CED of methotrexate and 125I-UdR with concomitant 
systemic temozolomide was safe and very effective leading to 100% survival in an orthotopic xenograft 
glioblastoma model. Therefore, this therapeutic strategy may be a promising option for future 
glioblastoma therapy. 
Key words: Glioblastoma, Auger-electron therapy, convection-enhanced delivery, [125I]5-Iodo-2’-deoxyuridine, 
temozolomide. 
Introduction 
Glioblastomas (GBMs) – the most common and 
malignant primary brain tumor – always recur after 
standard treatment consisting of surgery, radiation 
and chemotherapy. The overall median survival is 
only approximately 15 months following surgical 
resection, adjuvant external radiotherapy and 
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concomitant and adjuvant alkylating chemotherapy 
using temozolomide (TMZ) [1, 2]. Due to their 
invasive nature, GBMs are non-curable by surgery 
and side effects as well as poor blood-brain-barrier 
(BBB) penetration of most drugs are dose-limiting for 
conventional radio- and chemotherapy [3]. Sub-lethal 
doses may, therefore, favor escape of cancer cells from 
standard therapy and, thus, new therapeutic 
strategies to eradicate GBMs are needed.  
A novel promising therapeutic tool that may 
circumvent conventional resistance comprises 
short-range Auger-electron-emitters (AEEs). The 
decay of AEEs creates multiple, highly localized 
ionizations (medium to high linear energy transfer 
(LET): 4-26 keV/µm) possible of causing highly 
damaging radiation effects in cells that may result in 
superior properties for AEE-based therapeutic 
strategies [4, 5]. The primary radiobiological effect 
responsible for cell killing is believed to be creation of 
DNA double-strand breaks, especially if the AEE is 
bound to the DNA [6], though other possible targets 
have been suggested lately [7, 8]. This is a 
consequence of the emission of an electron cascade in 
each radioactive decay, with all electrons having low 
energies (eV to keV) and thus short ranges in 
biological tissue. For the majority of the electrons in 
the cascade their range is typically limited to less than 
the diameter of a single cell (2-500 nm). Therefore, 
AEEs are able to provide an extremely high local 
radiation dose, which may minimize toxic adverse 
effects to normal tissues due to cross-fire irradiation. 
However, to achieve this, selective delivery of the 
AEEs to the genomic DNA of the cancer cells is 
required. Hence, we hypothesized that using the 
highly toxic AEE compound 
[125I]5-Iodo-2’-deoxyuridine, we could effectively 
eradicate GBM cells in vitro and in vivo.  
Since 125I-UdR is nonspecifically taken up by all 
DNA-synthesizing cells in the body [9] combined 
with a very short systemic biological half-life [10], it 
has to be delivered locally in the central nervous 
system to induce a significant antitumor effect in 
brain tumors and avoid systemic adverse effects. In 
several clinical trials (reviewed by Vogelbaum & 
Iannotti [11]), new compounds for the treatment of 
GBMs have been administered by so-called 
convection-enhanced delivery (CED) [12]. This 
approach involves continuous infusion of a drug 
under positive pressure. In practice, one or several 
catheters connected to an infusion pump are placed in 
the brain parenchyma, most often in areas of residual 
tumor. This bypasses the BBB and a high 
concentration of the drug is obtained in the brain with 
no or very little systemic toxicity [11, 12]. Therefore, 
the CED method was chosen for 125I-UdR 
administration. The radiotherapeutic effects of 
125I-UdR can be further increased by exposing the 
tumor cells to methotrexate (MTX) prior to the 
125I-UdR, which increases the percentage of cells 
undergoing DNA replication and, simultaneously, 
increases the DNA-incorporation of 125I by 
thymidylate synthetase inhibition [13]. 
The overall aim of this study was to test the 
effect and safety profile of 125I-UdR therapy in vitro 
and in vivo on immature GBM spheroid cultures 
(GSCs) [14-16] and orthotopic xenografted 
GBM-bearing rats, respectively. Moreover, we aimed 
to determine if a further therapeutic effect was 
achieved when combining 125I-UdR therapy with the 
currently used first-line chemotherapeutic agent TMZ 
[1].  
Material and Methods 
Chemicals and Radiosyntheses 
125I-UdR was either purchased from Perkin 
Elmer (Skovlunde, Denmark) or prepared essentially 
as described by Wang et al. [17] using 
trimethylstannyl-2'-deoxyuridine as precursor. The 
final product was sterilized by passing the eluate 
through a 0.22 µm sterile filter into a capped vial. 
MTX (Sigma-Aldrich, Copenhagen, Denmark) and 
TMZ (Sigma-Aldrich) was prepared according to the 
manufacturer’s instructions. MTX (1 mM) and TMZ 
(129 mM) were stored at -20 °C and diluted in fresh 
medium for in vitro studies right before each use. 
The amino-acid tracer [11C]methylaminoiso-
butyric acid ([11C]MeAIB) was prepared as described 
previously [18]. 
Cell Culture 
Cells were cultured as free-floating spheroids in 
serum-free medium at 36°C in a humidified incubator 
with 5% CO2 [19]. Two immature GSCs, passage 9-12, 
designated T78 and T87, were utilized. These were 
both derived from males in 2009 and 2010, 
respectively. They were established and 
characterized, as previously described [19, 20] in our 
laboratory according to approval by the Regional 
Scientific Ethical Committee (approval number 
S-VF-20040102). These GSCs have the ability to form 
new spheroids at clonal density, a karyotype typical 
of GBMs, and the ability to form highly invasive 
tumors upon orthotopic xenografting. Moreover, they 
differentiate into cells expressing neuronal, astrocytic 
and oligodendrocyte markers upon culturing in 
serum-containing medium. Both GSCs were derived 
from mutated isocitrate dehydrogenase 1 (mIDH1) 
negative tumors representing primary GBMs [21] and 
both have a hypermethylated O6-methylguanine- 
DNA methyltransferase (MGMT) promoter region 
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indicating sensitivity to TMZ [22]. 
Viability Assay 
T78 and T87 cells cultured as spheroids were 
trypsinized and seeded in 96-well plates in serum-free 
medium (1,000 cells/well). The next day, the cells 
were incubated in either increasing activities of 
125I-UdR (0-3 kBq/ml) or the “cold”, non-radioactive, 
but chemically identical, 127I-UdR (12 pg/ml, 
corresponding to the mass concentration of 3 kBq/ml 
125I-UdR, Sigma-Aldrich). To investigate the 
additional effect of MTX and TMZ co-exposure, cells 
were incubated with 125I-UdR as above with 0.01 μM 
MTX added or with 0.01 μM MTX plus equipotent 
concentrations of TMZ added, i.e., 10 μM and 100 μM 
TMZ for T78 and T87 cells, respectively. At day 7, 20 
μl of CellTiter Blue (Promega, Nacka, Sweden) was 
added and the cells were returned to the incubator for 
6 hours prior to recording of the absorbance in a 
Elx800 microplate reader (BioTek, Brondby, 
Denmark).  
Migration Assay 
Geltrex (Gibco, Naerum, Denmark) and 
serum-free medium was mixed (1+49) and 1.4 ml was 
added to each well in 12-well plates. Coated plates 
were incubated over night at 36°C and the following 
morning the supernatant was aspirated. One spheroid 
(100-200 µm) was embedded in the coating per well. 
After incubating the plate for 75 minutes at 36°C, 800 
µl serum-free medium was added. When spheroids 
started migrating (designated day 0) additionally 200 
µl of serum-free medium (serving as untreated 
controls), 127I-UdR or 125I-UdR was added resulting in 
a final concentration of 0.3 µg/ml or 3 kBq/ml, 
respectively. Images were obtained daily from day 0 
through day 5 using a Leica DM IRB inverted 
phase-contrast microscope, a Leica DFC300FX 
camera, and the Leica Application Suite version 2.6.0 
RI computer software. The spheroid radius was 
determined (http://imagej.nih.gov/ij/) and the 
migration speed/day was calculated. 
Nuclear Uptake and Clonogenic Assay 
The amount of radioactivity in the cell nuclei 
was determined by incubating T87 cells with 0, 0.5, 1, 
2 and 3 kBq/ml 125I-UdR, respectively, for 24 h. Cells 
were counted, washed in PBS and fractionated using 
the Nuclei EZ Prep Nuclei isolation kit 
(Sigma-Aldrich) as described previously [23].  
For the clonogenic assay, T87 cells were seeded 
into poly-L-Lysine coated 6-well plates and incubated 
with the same 125I-UdR activity concentrations as 
above for 24 h followed by 7 d incubation in 
serum-free medium. Cells were stained with 0.05% 
Crystal Violet and colonies larger than 50 cells were 
counted using the colony counter from the 
ImageQuantTL software (GE Healthcare, Brondby, 
Denmark). An estimate of the absorbed radiation dose 
to the cell nuclei was calculated using the MIRD 
cellular approach [24] from the measured mean 
activity uptake per cell nucleus. Since 125I-UdR is 
taken up by the cells and bound to the DNA 
indefinitely and the half-life of 125I is long compared to 
the duration of the assay, the activity per cell nucleus 
decreases over time primarily due to cell division. 
Hence, the effective half-life was assumed to be equal 
to the T87 cell doubling time, which was measured to 
be 22 h. By integrating the area under the time-activity 
curve per nucleus, the total number of cumulative 
decays was found. Only the self-dose from activity in 
the nucleus was considered, since the dose 
contribution from activity in the cytoplasm was 
negligible as is the cross-dose contribution for 
125I-UdR [25]. The mean absorbed radiation dose to 
the nucleus could then be calculated by multiplying 
the cumulative decays in the nucleus by the tabulated 
S-value, S(N←N) = 2.12*10-3 Gy/(Bq s) [24], for a 
measured mean cell nucleus radius of approximately 
6 µm. 
In Vivo Experimental Setup 
To test the effect and safety of 125I-UdR-based 
Auger-electron therapy with and without 
concomitant TMZ, an in vivo experiment was set up as 
illustrated in Fig. 1. 
Animal Model and In Vivo Auger-Therapy 
All animal procedures were conducted in 
accordance with the obtained approval from the 
national Animal Experiments Inspectorate (permission J. 
Nr. 2008/561-1572). Male athymic nude rats (n=48) 
aged six weeks (Hsd:RH-Foxn1rnu, Harlan 
Laboratories, Venray, Nederlands) were 
anaesthetized subcutaneously (mixture of Hypnorm 
and Midazolam) and placed in a small animal 
stereotaxic instrument (Model 900, David Kopf 
Instruments, Tujunga, USA). Through a burr hole 
placed one mm anteriorly and two mm laterally to 
bregma a 2 µl cell suspension of 300,000 T87 single 
cells in Hank’s Balanced Salt Solution (Gibco) 
supplemented with 0.9% glucose (SAD 500 mg/ml) 
was slowly injected at a depth of 3.5 mm. Two weeks 
later, SMP-200 iPRECIO® Micro Infusion Pumps 
(Data Sciences International, MC s’Hertogenbosch, 
Nederlands) were implanted subcutaneously in 32 
rats, since preliminary experiments had shown 
establishment of tumors at this time point. Rats were 
anaesthetized and fixated as described above and the 
midline incision was re-incised and the burr hole was 
identified. A 4 mm pump connector cannula 
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(PlasticsOne, Roanoke, Virginia, USA) was then 
connected to the pump catheter and implanted with 
the tip of the cannula in the center of the bulk tumor. 
Pumps were programmed to instant mode, constant 
flow mode and 5 µl/hour infusion rate and loaded 
with isotone saline (n=8, group 2) or 0.1 mM MTX 
(n=24, group 3, 4 and 5). This concentration of infused 
MTX has previously been shown to effectively 
increase the DNA-incorporation of 125I in intrathecal 
tumor cells in rats [13]. As one rat with an MTX 
loaded pump never woke up after surgery it was 
censored from the study. Two days later the 31 rats 
were anaesthetized using isoflurane, and residual 
saline or MTX was extracted from the pump 
reservoirs. The reservoirs were re-filled with 960 µl of 
0.3 µg/ml 127I-UdR (n=16, group 2 and 3, 
corresponding to approximately the same number of 
I-UdR molecules as for the 125I-UdR-groups) or with 
the 125I-UdR activity (n=15, group 4 and 5), enabling 8 
days of continuous infusion and a cumulated infused 
125I-UdR activity of 83 ± 7 MBq. Initiated on the same 
day, eight of these rats (group 5) had a daily 
intraperitoneal (IP) injection of 200 mg/m2 TMZ 
(Sigma-Aldrich) dissolved in 10% DMSO 
(Sigma-Aldrich) v/v 0.9% NaCl for five consecutive 
days. Two additional groups received either no 
treatment (n=8, group 1, serving as control group) or 
systemic TMZ treatment (n=8, group 6) by daily IP 
injections of 200 mg/m2 TMZ for five consecutive 
days as above.  
The rats were fed ad libitum and to block the 
thyroid gland, potassium iodine (KI, Sigma-Aldrich) 
was added to the drinking water (1 mg/ml) from the 
day of pump implantation and the following 14 days. 
At the end of the observation period (180 days after 
completion of treatment) or once animals reached the 
pre-determined humane endpoints (neurological 
deficits or >20% weight-loss) they were euthanized.  
Distribution Evaluation by SPECT/CT 
The intracranial distribution of infused 125I-UdR 
was evaluated on the last day of infusion using a 
Siemens Inveon Small Animal PET/SPECT/CT 
scanner. The animals (n=4) were anesthetized using 
isoflurane and subsequently SPECT scanned for 
approximately 42 min. The images were reconstructed 
using the OSEM3D algorithm. In one of the animals a 
low-dose CT scan was performed in combination with 
the SPECT scan.  
 
 
 
Figure 1. Schematic view of the in vivo study in orthotopic xenografted GBM-bearing rats. 
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Tumor Growth Evaluation by PET 
For tumor growth evaluation, the animals were 
PET scanned biweekly in the initial phase and later 
every third week using the Inveon PET scanner. 
Briefly, the animals were anesthetized using 
isoflurane and injected via the tail vein with 50 MBq 
[11C]MeAIB, a metabolically stable alanine analogue 
targeting the amino-acid transport system A [26, 27]. 
Forty minutes after tracer injection pairs of animals 
were placed head-to-head in the scanner and a 14 min. 
static scan was performed. The acquired data were 
reconstructed using the OSEM2D algorithm without 
scatter and attenuation correction in the Inveon 
Acquisition Workplace software module (Siemens, 
Knoxville, USA). 
Blood Sampling 
Blood samples were taken 3 weeks 
pre-treatment, and 3, 5, 13 and 26 weeks 
post-treatment to evaluate serological signs of 
potential toxicity. Due to limitations in blood 
collection volume, rats from each treatment group 
were divided in two groups; one for thyroid and one 
for hepatic, renal and bone marrow toxicity 
evaluation.  
 During anesthesia, blood samples were collected 
via the tail vein. Thyroid function was evaluated 
using total T3 and T4 ELISA kits (Nordic Biosite, 
Copenhagen, Denmark) on plasma samples. Plasma 
levels of alanine aminotransferase (ALT), creatinine 
and blood urea nitrogen (BUN) were analyzed on a 
Cobas Mira Plus (Roche Diagnostics, Hvidovre, 
Denmark) analyzer. Whole blood levels of potassium 
and sodium were analyzed on a GEM Premier 3000 
analyzer (Instrumentation Laboratory, Massachusetts, 
USA). Hemoglobin (Hb), white blood cell (WBC) and 
platelet counts were determined in whole blood using 
a scil Vet ABC Hematology Analyzer and the rat 
species-specific smart card (scil animal care company, 
Viernheim, Germany). All analyses were carried out 
in accordance with the manufacturers’ instructions.  
Histology 
Brain, thyroid gland, liver and kidneys were 
removed post-mortem and fixed in 4% formaldehyde. 
After fixation, brains were divided in 1 mm thick 
coronal sections using a rat brain matrix (PlaticsOne) 
followed by paraffin embedment. Thyroid gland, liver 
and kidneys were paraffin embedded as well. Three 
µm sections were cut and all sections were stained 
with hematoxylin and eosin (HE) for morphological 
evaluation. To evaluate the human-derived brain 
tumors, brain sections were immunohistochemically 
stained with an antibody targeting human vimentin. 
This was carried out using the AutostainerPlus (Dako, 
Glostrup, Denmark) as follows. Sections were 
deparaffinized and heat-induced epitope retrieval 
was performed in a buffer solution consisting of 10 
mM Tris-base and 0.5 mM ethylene glycol tetraacetic 
acid, pH 9. After blocking of endogenous peroxidase 
activity by incubation in 1.5% hydrogen peroxide, 
sections were incubated with primary antibody 
against human vimentin (clone SP20, Nordic Biosite, 
1+200) for 60 minutes. The antigen-antibody complex 
was detected using PowerVision (Novocastra, 
Newcastle upon Tyne, UK) and visualized with 
3,3′-diaminobenzidine as chromogen. Sections were 
then counterstained with Mayers Haematoxylin, and 
coverslips were mounted using AquaTex. Omission of 
primary antibodies served as negative controls and 
controls for non-specific staining related to the 
detection systems. All slides were scanned on a 
Hamamatsu Digital Slide Scanner (Hamamatsu, 
Japan). Additionally, kidney sections were periodic 
acid-Schiff (PAS) and liver PAS-diastase stained to 
complement the morphological evaluation.  
Statistical Analysis 
In vitro and blood sample data were analyzed 
with unpaired, two-tailed Student’s t-tests or two-way 
ANOVA with Holm-Sidak’s correction for multiple 
comparisons in GraphPad Prism. A p-value of < 0.05 
was considered statistically significant. The 
Kaplan-Meier-survival data were analyzed using the 
log-rank (Mantel-Cox) test correcting for multiple 
comparisons. A Bonferroni-corrected p-value of 
< 0.05/9 was considered statistically significant. 
Results 
Cell Viability and Spheroid Migration In Vitro 
In vitro, the effects of 125I-UdR were tested on two 
immature GSCs. As seen in Fig. 2A, an 
activity-dependent reduction in cell survival was 
found in both cell lines. The cell survival was 
significantly decreased (p<0.0001) in T78 for all 
125I-UdR activity concentrations used, when compared 
to untreated controls, while 1000 Bq/ml or more were 
required in T87 GSCs to obtain a significant 
therapeutic effect. This difference in the response to 
the 125I-UdR therapy between the T78 and T87 GSCs, 
with T87 being the most resistant, was highly 
significant (p<0.0001). In both cell lines, the 
therapeutic effects of 125I-UdR were also significantly 
higher compared to the chemically identical, but 
nonradioactive, 127I-UdR for most activity 
concentrations tested. Co-treatment with MTX 
significantly increased the therapeutic effect of 
125I-UdR in the T87 GSCs at activity concentrations 
between 250 and 1000 Bq/ml (p<0.0001), while 
significance was only reached at one activity 
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concentration (100 Bq/ml) in T78 GSCs. By combining 
MTX and 125I-UdR with an equipotent amount of 
TMZ, a significant further increase in the therapeutic 
effect was observed for both cell lines compared to 
MTX + 125I-UdR or 125I-UdR alone, except at the 
highest activity concentrations tested (Fig. 2A). 
 To test the anti-migratory effect of 125I-UdR a 2D 
migration assay based on migration of spheroids on a 
coating of reduced growth factor basement membrane 
extracts was applied. As opposed to many other 
migration assays, it does not rely on serum-based 
chemo-attraction and may, therefore, imitate the in 
vivo migration better. As illustrated (Fig. 2B + 
supplementary Fig S1), spheroid migration was 
significantly reduced by 125I-UdR in T78 and T87 
GSCs from day three, compared to 127I-UdR treated 
spheroids serving as control.  
 Clonogenic survival was measured for 125I-UdR 
in the T87 GBM cell line only, as this cell line was 
chosen for the following in vivo therapy in rats. As can 
be seen in Fig. 3, the surviving fraction decreased as 
function of an increasing nuclear uptake of 125I-UdR 
and resulting increasing absorbed radiation dose to 
the nuclei of the GBM cells. 
 
 
Figure 2. Antiproliferative effects in T78 and T87 GBM cells (A) exposed to increasing activity concentrations of 125I-UdR, MTX+125I-UdR or MTX+125I-UdR+TMZ 
or corresponding groups with stable 127I-UdR, and anti-migratory effects (B) of T78 and T87 spheroids exposed to either 127I-UdR or 125I-UdR. Error bars represent 
SEM for three independent CellTiter Blue assays (n=4) or five independent wells per group in the migration assay. NS: p > 0.05; *: p < 0.05; **: p < 0.01; ***: p < 0.001; 
****: p < 0.0001. 
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Figure 3. Clonogenic survival of T87 GBM cells as a function of the mean cell 
nucleus uptake of 125I-UdR and resulting mean absorbed dose to the cell nuclei. 
Error bars represent SD for three independent assays (n=3). 
 
125I-UdR Intracerebral Distribution 
By intratumoral CED of 125I-UdR for 8 days in 
orthotopic GBM-bearing rats, a high concentration of 
125I was found in the tumor region determined by 
combined SPECT/CT (Fig. 4, n=1) or SPECT alone 
(n=3, data not shown). Moreover, a small fraction of 
the 125I could be seen in the contralateral hemisphere 
and in the posterior part of the brain, allowing for 
irradiation of possible distantly located migrating 
GBM cells.  
In Vivo Effects 
The 47 orthotopic xenografted T87 GBM-bearing 
rats were treated with: 1) no treatment (control), 2) 
127I-UdR by CED, 3) neoadjuvant MTX + 127I-UdR by 
CED, 4) neoadjuvant MTX + 125I-UdR by CED, 5) 
neoadjuvant MTX + 125I-UdR by CED + concomitant 
systemic TMZ, or 6) systemic TMZ as monotherapy, 
as outlined in Fig. 1. Tumors rapidly progressed in all 
animals in group 1, 2 and 3, as determined by 
[11C]MeAIB PET (Fig. 5A). The median survival in 
these groups were 24, 21 and 30.5 days, respectively, 
after treatment start (Fig. 6). In group 1 and 3, no 
animals survived longer than 35 days after initiation 
of treatment due to massive tumor burden, while in 
group 2 the longest survival time was only 23 days. 
Tumor progression in group 4 was strongly delayed 
and only three out of seven animals in this group 
developed a PET-detectable tumor during the 180 
days of observation. The time from therapy initiation 
to the first PET–based tumor detection in this group 
was 91 days and four animals (4/7, 57%) survived the 
entire observation period. None of the animals in 
group 5 developed a PET-detectable tumor during the 
180-day observation period and all animals (8/8, 
100%) survived this period. The median survival 
in group 6 subjected to TMZ monotherapy was 47 
days with no animals surviving longer than 50 days 
after initiation of treatment.  
 The survival benefit of neoadjuvant MTX + 
125I-UdR as stand-alone Auger-therapy (group 4) was 
highly significant compared with the non-radioactive, 
but chemically identical treatment MTX + 127I-UdR 
(group 3, p=0.0001) or untreated controls (group 1, 
p<0.0001). Importantly, the Auger-therapy was also 
significantly better than the systemic 
TMZ-chemotherapy alone (group 6, p=0.0001). The 
survival benefit of neoadjuvant MTX + 125I-UdR with 
concomitant, systemic TMZ (group 5) was also highly 
significant (p<0.0001) compared with these groups. 
However, the added therapeutic effect of the 
concomitant TMZ treatment (group 5) compared to 
the Auger-therapy (group 4) alone was not found 
significant (p=0.04). 
 
 
Figure 4. Axial (A) 
and sagittal (B) 
SPECT/CT images 
of a rat after 
125I-UdR infusion 
showing the 125I 
activity distribution 
in the brain. The 
black arrow 
indicates the 
isocenter of 
delivery. L:left, 
R:right, A:anterior, 
P:posterior. 
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Figure 5. Transaxial [11C]MeAIB PET images and corresponding post-mortem immunohistochemical anti-human vimentin stained coronal brain sections obtained 1–2 
days later. (A) PET image of a rat from group 4 showing a very large tumor (white arrow), confirmed by histology. (B-C) PET images of rats from group 4 and 5 
scanned 178 days after treatment start showing no PET detectable tumors. Histology showed empty tumor beds with either only a few GBM cells located in the 
ipsilateral hemisphere (B) or no identifiable GBM cells (C). Scale bar 1 mm. 
 
Figure 6. Kaplan-Meier plot showing that the survival benefit of neoadjuvant MTX + 125I-UdR as stand-alone Auger-therapy (group 4) or with concomitant, systemic 
TMZ chemotherapy (group 5) was highly significant compared with the non-radioactive, but chemically identical treatment MTX + 127I-UdR (group 3, p=0.0001 and 
p<0.0001, respectively) or untreated controls (group 1, both p<0.0001). The Auger-therapy was also significantly better than systemic TMZ-chemotherapy alone 
(group 6, p=0.0001). 
 Theranostics 2016, Vol. 6, Issue 12 
 
http://www.thno.org 
2286 
 Post-mortem histology of the brains revealed that 
all animals in group 1, 2, 3 and 6 had very large 
tumors (Fig. 5A) explaining their short survival. The 
three animals in group 4, not surviving the entire 
observation period, had large tumors as well. The 
remaining animals in this group had an empty 
tumor-bed (the tissue surrounding the original bulk 
tumor) with a few GBM cells located in the ipsilateral 
hemisphere (Fig. 5B). No distant migratory cells could 
be identified. In group 5, five animals had the same 
histological appearance as just described, whereas no 
vimentin positive GBM cells could be detected in 
brains of the remaining three animals (Fig. 5C). 
Adverse Effects 
The local administration of MTX and 125I-UdR by 
CED as well as IP administration of TMZ could 
potentially give rise to local and/or systemic adverse 
effects. To evaluate this, blood samples (Fig. 7) were 
examined and post-mortem histological analyses 
performed (Fig. 8). 
 
 
Figure 7. Evaluation of adverse effects by blood samples before and after treatment. (A) White blood cell and (B) platelet levels. (C) Plasma total T3 and (D) total 
T4 thyroid hormone blood levels. (E) Plasma creatinine and (F) BUN blood levels. 
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Figure 8. Evaluation of adverse effects by histology. (A) Thyroid gland HE staining from group 2 showing normofollicular architecture. (B) Similar HE staining from 
group 4 showing microfollicular architecture and colloids with scalloped margins (black arrow). (C) Liver PAS-diastase staining from group 2 showing normal liver 
architecture and no signs of hepatocyte necrosis, haemorrhage or inflammation. (D) Liver PAS-diastase staining from group 5, showing a few necrotic hepatocytes 
(black arrow). The liver architecture was normal and without haemorrhages. (E-F) Kidney PAS staining from group 2 and 4 showing no histopathologic findings. Scale 
bar 100 µm. 
 
 In general, no animal presented with 
neurological deficits or signs of discomfort indicating 
brain-related adverse effects due to the infused drugs 
or the CED procedure itself. All animals reaching the 
humane endpoint of >20% weight-loss had large 
tumors explaining their terminal weight-loss. No 
relevant histopathological findings were observed in 
the non-tumor infiltrated brain parenchyma. Total T3 
and T4 levels in the Auger-therapy groups 
diminished to some extend post-treatment, but the 
drop stabilized from 13 to 26 weeks’ post-treatment 
(Fig. 7). Histologically, animals in group 4 and 5 
presented with microfollicular thyroid gland 
architecture and colloids with scalloped margins, 
indicative of stimulated and active glands (Fig. 8). 
Normofollicular architecture was found in the 
remaining groups. Hepatic function was evaluated by 
plasma ALT and BUN. No increase in ALT was 
observed in any of the groups (supplementary Fig. 
S2). BUN, which encompasses both hepatic 
(production) and renal (excretion) functions, 
increased after treatment start, but returned to 
baseline at 26 weeks. In all groups the liver 
architecture was normal. There were no signs of 
hepatocyte necrosis, haemorrhage or inflammation in 
all groups except group 5. In this group, a few cases of 
slight portal tract edema were observed and focally a 
few necrotic hepatocytes were present (Fig. 8). Renal 
function was assessed by plasma creatinine and 
whole blood potassium and sodium and to some 
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degree plasma BUN. In all groups, creatinine initially 
increased (Fig. 7), whereas potassium decreased after 
treatment start while sodium remained stable 
throughout the study (Supplementary Fig. S2). In all 
groups, the kidneys appeared histologically normal 
without signs of tubular or glomerular damage or 
interstitial fibrosis (Fig. 8). Bone marrow function was 
assessed by whole blood Hb, WBC and platelets. No 
sign of bone marrow suppression was observed. 
Discussion 
As hypothesized, the use of the 
DNA-incorporating AEE compound 125I-UdR alone or 
in combination with TMZ effectively eradicated GBM 
cells by high-LET Auger-electron cascades. As seen in 
Fig. 2, viability and migration were significantly 
reduced in vitro in immature GSCs using very low 
activity concentrations of 125I-UdR and by 
concomitant TMZ treatment further cytotoxicity was 
achieved. This illustrates the therapeutic potential of 
DNA-incorporated AEEs, which has been 
documented in many cell lines [28, 29]. 125I decays via 
electron capture accompanied by a high degree of 
internal conversion, which results in nearly two 
Auger-electron cascades with on average 
approximately 20 electrons per decay. This gives rise 
to a very high radiation dose close to the decay site 
and high LET values (4-26 keV/µm) approaching 
those observed with α-particles (~80 keV/µm). The 
complex double-strand breaks created by these 
Auger-electron cascades from DNA-incorporated 
AEEs are very difficult for the cells to repair leading to 
cell death or loss of proliferative capacity [4]. 
 The profound therapeutic response observed in 
vivo in the two 125I-UdR treated groups (Fig. 6) was 
confirmed by immunohistochemical vimentin 
staining as no residual bulk tumors were left (Fig. 
5B-C). However, in 7/7 (100 %) rats in group 4 and 
5/8 (63 %) rats in group 5, a few tumor cells were 
found near the original tumor-bed (Fig. 5B) 180 days 
after treatment start. These cells could represent 
cancer stem cells that survived the treatment [30, 31]. 
Alternatively, the remaining cells may represent 
non-clonogenic cells that have lost their ability to 
divide and, thus, from a radiobiological point of view 
could be regarded as “dead” cells, i.e. not being able 
to repopulate the tumor [32].  
 In the in vivo study, the infused 125I-UdR activity 
concentration was approximately 4-6 orders of 
magnitude higher than in the in vitro studies. The high 
concentration was chosen to ensure that distantly 
located migratory GBM cells were exposed to 
125I-UdR. Moreover, 125I-UdR was delivered by CED, 
relying on a pressure-driven bulk flow created by a 
small pressure gradient [12], to increase the regional 
distribution as compared to simple passive diffusion 
[11]. This was confirmed by SPECT/CT, showing that 
125I-UdR was distributed far away from the catheter 
tip (Fig. 4). As expected, SPECT/CT showed a decline 
in 125I activity concentration in the contralateral 
hemisphere and the caudal part of the brain compared 
to the isocenter of delivery. For that reason, more than 
one catheter has been applied in the majority of 
clinical CED trials [33, 34]. Technically, this is difficult 
in small animals as opposed to a full-sized human 
brain, where it will likely be required to obtain a 
reliable and widespread MTX + 125I-UdR intracerebral 
distribution. Barua et al. recently demonstrated in a 
glioblastoma patient, that it is possible to obtain a 
carboplatin distribution covering both the tumor 
volume and peri-tumoral penumbra using a 
transcutaneous bone-anchored port for CED [35]. 
Hence, CED of 125I-UdR including neoadjuvant MTX 
leading to a full tumor coverage of the compounds 
should be clinically achievable. By using the imaging 
analogue, 124I-UdR, which is chemically and thus, 
biologically identical to the therapeutic compound, it 
will be possible to determine the distribution and 
kinetics of the compound in the brain of the patient 
using PET imaging and to optimize the CED 
parameters prior to the therapy. Therefore, a 
patient-specific treatment may be possible using the 
theranostic pair 124/125I-UdR. 
 Infusion of 125I-UdR into rat brain tumors has 
previously been performed by Kassis et al., who used 
the syngeneic 9L rat gliosarcoma model and infused 
6.9-8.8 MBq 125I-UdR intracerebrally for 1.5 or 6 days 
with a 10-fold lower infusion rate than in the current 
study [36]. They observed the best therapeutic 
response in animals with cells inoculated the day 
before and, thus, being without an established tumor. 
The median survival increased from 18 to 26 days and 
20% of the 125I-UdR treated animals survived more 
than 85 days. In animals with established tumors, the 
median survival increased from 24 to 28.5 days. The 
explanation for the pronounced increase in 
therapeutic response in the current study, using 
animals with established tumors, is probably 
multifaceted. A much higher amount of cumulated 
activity was infused (approximately 80 MBq vs. 8.8 
MBq), a 10-fold higher infusion rate was applied and 
the infusion period was prolonged to 8 days. This 
presumably results in a higher and a wider 
intracerebral activity distribution allowing 
eradication of both bulk tumor and distantly located 
GBM cells leading to a better effect. The prolonged 
infusion increases the probability that all tumor cells 
will undergo DNA synthesis during the infusion 
period, and thus, incorporate 125I-UdR. Finally, we 
applied neoadjuvant MTX, which is known to 
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increase the percentage of cells undergoing DNA 
replication and, simultaneously, to increase the 
DNA-incorporation of 125I-UdR by thymidylate 
synthetase inhibition, leading to a better therapeutic 
effect in vivo as investigated by Kassis et al. [13, 37]. 
The authors found that pre-infusion of MTX prior to 
125I-UdR therapy of spinal cord tumors in rats, 
enhanced the 125I-UdR tumor uptake a factor of 2 
compared to 125I-UdR alone and led to a longer 
median survival. In the present study, 57% in group 4 
became long-term survivors, and with the addition of 
TMZ the survival rate increased to 100% in group 5 
(Fig. 6). This emphasizes the importance of not only 
local, but also regional, intracerebral distribution of 
high activity concentrations of 125I-UdR, which is 
obtainable by CED as opposed to local implant 
techniques [12, 38]. Additionally, the pronounced 
effect observed in group 5 of targeting the tumor cell 
DNA using two drugs (125I-UdR and TMZ) with 
different DNA targeting mechanisms became evident. 
A therapeutic effect of MTX itself was not anticipated 
in the present study. The increase in median survival 
with MTX + 127I-UdR was only approximately 6 days 
compared to untreated controls (non-significant, 
p=0.02). In comparison, systemic TMZ treatment 
alone increased the median survival 23 days 
(p<0.0001) compared to untreated controls. Hence, the 
considerable survival rate observed in the current 
study using 125I-UdR Auger-therapy emphasizes the 
therapeutic potential of this novel type of 
GBM-treatment compared to the currently used 
first-line chemotherapeutic agent TMZ. In GBM 
patients, the addition of concomitant TMZ 
chemotherapy to external radiotherapy increases the 
median survival from 12.1 to 14.6 months [39], so the 
proposed Auger-therapy could potentially have a 
significant impact on future GBM treatment – either 
alone or in combination with TMZ and external 
radiotherapy. 
 No animals showed objective signs of 
neurotoxicity. The same was reported in, to our 
knowledge, the only existing study on administration 
of 125I-UdR into the human central nervous system 
[40]. 125I-UdR entering the systemic circulation has a 
short biological half-life of only five minutes due to 
rapid catabolization and dehalogenation resulting in 
125I-uracil and free 125I- [10]. None of these compounds 
are incorporated into the genomic DNA during cell 
division in normal tissue (as the 125I-UdR), which is 
required for high-LET-like radiotoxic effects and, 
hence, no severe adverse effects were anticipated. In 
line with this, blood parameters evaluating the bone 
marrow, harboring some of the most rapidly dividing 
cells in the body, remained unaffected. However, 
since athymic nude rats lacking mature T cells were 
used in the current study, further studies in 
immunocompetent rats should ideally be performed 
to fully characterize the bone marrow toxicity profile 
for the treatment. 
 The kidneys are another important potential 
dose-limiting organ, because of their excretion of free 
125I. The treatment resulted in an increase in creatinine 
(Fig. 7), which remained, but apparently with little 
functional impact on the kidneys judged by the course 
of BUN and the excretion of potassium and sodium, 
and the lack of histological changes. However, to fully 
characterize the renal toxicity profile for the 
treatment, long-term studies (up to 12 months) in 
healthy rats will be required since late effects may 
show up at time points later than the six months used 
in the current study. To prevent uptake of free 125I- in 
the thyroid gland, the drinking water was 
supplemented with KI. Histologically, animals from 
group 4 and 5 had microfollicular thyroid architecture 
and colloids with scalloped margins (Fig. 8), which 
are signs of stimulated and active glands. This 
probably indicates that the thyroid blockings were not 
complete, leading to some uptake of free 125I-. 
However, the drop in total T3 and T4 blood levels in 
these groups during the study was considered 
irrelevant since the blood levels at the late time points 
were in the same range as those found for the 
untreated group 1. Furthermore, a drop in total T3 
and T4 was also observed in some of the 
non-radioactive groups, and thus, not related to 
radiation exposure. Finally, signs of hepatotoxicity 
were assessed. In group 5, a few animals presented 
with slight portal tract edema, and focally a few 
necrotic hepatocytes were present (Fig. 8). In the 
remaining groups, histology was inconspicuous. In 
contrast to MTX, which is known to be highly 
hepatotoxic [41], TMZ has only been reported 
casuistically to induce liver injury (toxic hepatitis) 
[42]. However, the histological changes observed in 
group 5 were only very subtle and in comparison, no 
changes were found in group 6 subjected to TMZ 
monotherapy. In addition, blood samples in all 
groups showed no evidence of sustained toxic effects 
and, therefore, we regard the treatments as being 
non-hepatotoxic. Summarized, CED of MTX + 
125I-UdR in combination with concomitant systemic 
TMZ proved safe without signs of dose-limiting 
adverse effects.  
Conclusion 
In conclusion, the multidrug approach including 
CED of MTX and the AEE-compound 125I-UdR in 
combination with systemic TMZ was safe and very 
effective in the orthotopic xenograft GBM model, 
leading to 100% survival. This suggests that this 
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AEE-based therapeutic strategy may be a promising 
new option in the treatment of patients suffering from 
– presently incurable – GBMs. 
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